Cipla Limited

NSE:CIPLA.NS

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

Location

India

Market Cap

USD 13.98 B

Share Price

USD 17.31

Avg Daily Volume

1,651,707

Change (1 day)

1.15%

Change (1 year)

-6.25%

Change (YTD)

-3.08%

Cipla Limited Depreciation And Amortization for the year ending March 31, 2025: USD 129.54 M

Cipla Limited Depreciation And Amortization is USD 129.54 M for the year ending March 31, 2025, a 14.75% change year over year. Depreciation and amortization are expense that reduces the value of tangible and intangible assets over their useful lives for tax and reporting purposes.

Cipla Limited Depreciation And Amortization for the year ending March 31, 2024 was USD 112.89 M, a -8.96% change year over year.
Cipla Limited Depreciation And Amortization for the year ending March 31, 2023 was USD 124.00 M, a -4.90% change year over year.
Cipla Limited Depreciation And Amortization for the year ending March 31, 2022 was USD 130.39 M, a -4.82% change year over year.
Cipla Limited Depreciation And Amortization for the year ending March 31, 2021 was USD 137.00 M, a -12.11% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Depreciation And Amortization	Dividends Paid	Common Stock Issued	Common Stock Repurchased

NSE: CIPLA.NS

Cipla Limited

CEO	Mr. Umang Vohra B.E., M.B.A.
IPO Date	Jan. 1, 1996
Location	India
Headquarters	Cipla House
Employees	27,764
Sector	🏥 Health Care
Industries Pharmaceuticals 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies

Description

Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.